A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults With Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose

Trial Profile

A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults With Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs TRX 518 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors GITR Inc; Leap Therapeutics
  • Most Recent Events

    • 13 Nov 2017 According to a Leap Therapeutics media release, patient follow-up, biopsy, and biomarker analysis of this trial are ongoing.
    • 11 Aug 2017 Status changed from recruiting to active, no longer recruiting, as reported in a Leap Therapeutics media release.
    • 11 Aug 2017 According to a Leap Therapeutics media release, the company has completed dose escalation phase and fully enrolled the expansion cohort of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top